Taylor B Engdahl
Overview
Explore the profile of Taylor B Engdahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuzmin I, Soto Acosta R, Pruitt L, Wasdin P, Kedarinath K, Hernandez K, et al.
Nat Commun
. 2024 Jul;
15(1):6421.
PMID: 39080316
The rodent-borne Andes virus (ANDV) causes a severe disease in humans. We developed an ANDV mRNA vaccine based on the M segment of the viral genome, either with regular uridine...
2.
Wolters R, Ferguson J, Nunez I, Chen E, Sornberger T, Myers L, et al.
Immunity
. 2024 Jun;
57(6):1413-1427.e9.
PMID: 38823390
Influenza B viruses (IBVs) comprise a substantial portion of the circulating seasonal human influenza viruses. Here, we describe the isolation of human monoclonal antibodies (mAbs) that recognized the IBV neuraminidase...
3.
Desautels T, Arrildt K, Zemla A, Lau E, Zhu F, Ricci D, et al.
Nature
. 2024 May;
629(8013):878-885.
PMID: 38720086
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs and revealed how quickly viral escape can curtail effective options. When the SARS-CoV-2 Omicron variant emerged in...
4.
Chapman N, Hulswit R, Westover J, Stass R, Paesen G, Binshtein E, et al.
Nat Commun
. 2023 Sep;
14(1):5650.
PMID: 37704627
The zoonotic Rift Valley fever virus (RVFV) can cause severe disease in humans and has pandemic potential, yet no approved vaccine or therapy exists. Here we describe a dual-mechanism human...
5.
Stass R, Engdahl T, Chapman N, Wolters R, Handal L, Diaz S, et al.
Nat Microbiol
. 2023 Jun;
8(7):1293-1303.
PMID: 37322112
Rodent-borne hantaviruses are prevalent worldwide and upon spillover to human populations, cause severe disease for which no specific treatment is available. A potent antibody response is key for recovery from...
6.
Engdahl T, Binshtein E, Brocato R, Kuzmina N, Principe L, Kwilas S, et al.
Elife
. 2023 Mar;
12.
PMID: 36971354
Hantaviruses are high-priority emerging pathogens carried by rodents and transmitted to humans by aerosolized excreta or, in rare cases, person-to-person contact. While infections in humans are relatively rare, mortality rates...
7.
Desautels T, Arrildt K, Zemla A, Lau E, Zhu F, Ricci D, et al.
bioRxiv
. 2022 Nov;
PMID: 36324800
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs, but also revealed how quickly viral escape can curtail effective options. With the emergence of the SARS-CoV-2...
8.
Wessel A, Doyle M, Engdahl T, Rodriguez J, Crowe Jr J, Diamond M
mBio
. 2021 Oct;
12(5):e0244021.
PMID: 34634945
Envelope protein-targeted vaccines for flaviviruses are limited by concerns of antibody-dependent enhancement (ADE) of infections. Nonstructural protein 1 (NS1) provides an alternative vaccine target that avoids this risk since this...
9.
Engdahl T, Kuzmina N, Ronk A, Mire C, Hyde M, Kose N, et al.
Cell Rep
. 2021 Jul;
36(3):109453.
PMID: 34289361
No abstract available.
10.
Engdahl T, Kuzmina N, Ronk A, Mire C, Hyde M, Kose N, et al.
Cell Rep
. 2021 May;
35(5):109086.
PMID: 33951434
New World hantaviruses (NWHs) are endemic in North and South America and cause hantavirus cardiopulmonary syndrome (HCPS), with a case fatality rate of up to 40%. Knowledge of the natural...